Ardelyx, Inc. Stock Plummets to New 52-Week Low of $3.90

Ardelyx, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 3.90 as of August 10, 2026. This marks a significant decline, reflecting a one-year performance drop of 38.08%, contrasting sharply with the S&P 500's gain of 21.34% during the same period. The company's financial metrics reveal a challenging landscape. Ardelyx reported a pre-tax profit of USD -37.6 million, a staggering decline of 148.04% year-over-year, while net profit also fell by 144.19%. The company’s debt-to-equity ratio stands at -0.36, indicating a precarious financial position. Additionally, the return on equity is reported at -36.90%, further highlighting the difficulties faced by the firm. With a market capitalization of USD 1,344 million, Ardelyx's price-to-book ratio is 8.05, suggesting that the stock may be trading at a premium relative to its book value. The company has not offered dividends, maintaining a yield of 0.00%. Overall, Ardelyx's recent performance underscores a period of significant financial strain and market volatility.